Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurogene Inc. - Common Stock
(NQ:
NGNE
)
35.02
-0.60 (-1.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurogene Inc. - Common Stock
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
August 09, 2024
NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
August 09, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
August 07, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene to Participate in BMO Genetic Medicines Summit
July 02, 2024
From
Neurogene Inc.
Via
Business Wire
MicroMarvel Neurogene Challenges Big Pharma
January 22, 2024
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases.
Via
Talk Markets
Neurogene Announces Addition to Russell 3000® Index
July 01, 2024
From
Neurogene Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 20, 2024
Via
Benzinga
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 18, 2024
Via
Benzinga
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
June 18, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene to Participate in Upcoming Conferences
June 05, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
June 03, 2024
From
Neurogene Inc.
Via
Business Wire
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
May 10, 2024
NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
May 10, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
May 07, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
April 22, 2024
From
Neurogene Inc.
Via
Business Wire
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Via
InvestorPlace
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
March 18, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
March 04, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene to Participate in Upcoming Investor Conferences
February 29, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
January 16, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Business Update and 2024 Outlook
January 05, 2024
From
Neurogene Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.